clinical trial · NCT06594679
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano·phase2·recruiting·n = 73
Ovarian CancerNiraparib Tosylate Monohydrate
brief summary
This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer. Target population will be patients (woman, age \> 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.
started
Sep 26, 2024
primary completion
Mar 20, 2027
completion
Sep 18, 2027
last updated
Mar 28, 2025
official title
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer: a Single Center, Open Label, Single Arm, Phase Ib/II Trial NICHOL TRIAL
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol